stockportfolio.pro
Stocks / BLTE vs PACS
BLTE vs PACS
Belite Bio, Inc and PACS Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Belite Bio, Inc (BLTE) | PACS Group, Inc. (PACS) | |
|---|---|---|
| Market cap | $5.5B | $5.5B |
| Revenue (latest FY) | $0 | $5.29B |
| Net income (latest FY) | $-77.61M | $191.54M |
| Revenue growth (5y CAGR) | — | 29.7% |
| Net margin | — | 3.6% |
| Return on equity | -10.1% | 20.2% |
| P/E ratio | — | 22.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 4 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BLTE — free Open PACS — freeFrequently asked questions
Which is bigger, BLTE or PACS?
Belite Bio, Inc is larger by market capitalization — $5.5B versus $5.5B.
Which grows faster, BLTE or PACS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.